Table 2:
Characteristics of adult donors whose hearts were accepted for transplant, by COVID status (April 2020 - March 2022)
| All transplanted donors | COVID(+) | COVID(−) | p-value6 | |
|---|---|---|---|---|
| Total n | 6464 | 187 (2.9%) | 6277 (97.1%) | |
| Demographics | ||||
| Female sex | 1818 (28.1%) | 34 (18.2%) | 1784 (28.4%) | 0.0021 |
| Age (mean ± SD), years | 32.8 ± 9.6 | 31.4 ± 8.4 | 32.8 ± 9.6 | 0.025 |
| Age 18 – 34 | 3852 (59.6%) | 124 (66.3%) | 3728 (59.4%) | 0.057 |
| Age 35 – 49 | 2219 (34.3%) | 59 (31.6%) | 2160 (34.4%) | 0.42 |
| Age 50+ | 393 (6.1%) | 4 (2.1%) | 389 (6.2%) | 0.022 |
| Race | ||||
| White | 4002 (61.9%) | 113 (60.4%) | 3889 (62%) | 0.67 |
| Black | 1195 (18.5%) | 37 (19.8%) | 1158 (18.5%) | 0.64 |
| Hispanic | 1070 (16.6%) | 32 (17.1%) | 1038 (16.5%) | 0.83 |
| Asian or Other | 197 (3.1%) | 5 (2.7%) | 192 (3.1%) | 0.76 |
| Comorbidities | ||||
| Obese (BMI ≥ 30 kg/m2) | 2006 (31%) | 64 (34.2%) | 1942 (30.9%) | 0.34 |
| Coronary artery disease1 | 111 (1.7%) | 1 (0.5%) | 110 (1.8%) | 0.21 |
| Smoking2 | 773 (12%) | 26 (13.9%) | 747 (11.9%) | 0.41 |
| Cocaine use2 | 1674 (25.9%) | 48 (25.7%) | 1626 (25.9%) | 0.94 |
| Intravenous drug use2 | 1153 (17.8%) | 36 (19.3%) | 1117 (17.8%) | 0.61 |
| Diabetes mellitus | 257 (4%) | 9 (4.8%) | 248 (4%) | 0.55 |
| Hypertension | 978 (15.1%) | 25 (13.4%) | 953 (15.2%) | 0.50 |
| Cardiac diagnostic findings | ||||
| EF3 | ||||
| < 40% | 26 (0.4%) | 1 (0.5%) | 25 (0.4%) | 0.77 |
| 40–49% | 56 (0.9%) | 2 (1.1%) | 54 (0.9%) | 0.76 |
| ≥ 50% | 6376 (98.7%) | 184 (98.4%) | 6192 (98.7%) | 0.81 |
| Wall thickness reported (%)4 | 4663 (72.1%) | 130 (69.5%) | 4533 (72.2%) | 0.42 |
| any LVH (≥ 1.2 cm) | 774 (16.6%) | 28 (21.5%) | 746 (16.5%) | 0.12 |
| mild LVH (1.2–1.3cm) | 599 (12.8%) | 25 (19.2%) | 574 (12.6%) | 0.027 |
| moderate+ LVH (≥ 1.4 cm) | 175 (3.8%) | 3 (2.3%) | 172 (3.8%) | 0.38 |
| Other clinical characteristics | ||||
| Blood type | ||||
| A | 2185 (33.8%) | 60 (32.1%) | 2125 (33.9%) | 0.61 |
| B | 679 (10.5%) | 20 (10.7%) | 659 (10.5%) | 0.93 |
| AB | 105 (1.6%) | 0 (0%) | 105 (1.7%) | 0.075 |
| O | 3495 (54.1%) | 107 (57.2%) | 3388 (54%) | 0.38 |
| Cardiac downtime5 | 2861 (50.2%) | 92 (54.8%) | 2769 (50.1%) | 0.23 |
| Inotrope use | 2025 (31.3%) | 47 (25.1%) | 1978 (31.5%) | 0.064 |
| Acidemia (pH < 7.35) | 805 (12.5%) | 31 (16.6%) | 774 (12.3%) | 0.083 |
Includes either reported history of coronary artery disease or positive coronary angiogram
Includes current or prior use
Calculated prevalence of EF by strata (< 40, 40–49…) includes only donors for which EF was reported
Calculated prevalence of LVH by strata (mild, moderate+) includes only donors for which either LV posterior or septal wall thickness was reported. LVH classification was based on the higher of these two measures.
Refers to the occurrence of cardiac arrest between the time of brain death and donor organ recovery. Calculated prevalence excludes 767 donors (19 COVID(+), 748 COVID−) for which downtime was coded as “unknown”.
Based on chi-squared test for categorical variables and t-test for continuous variables.
COVID = coronavirus-19; EF = ejection fraction; LVH = left ventricular hypertrophy